Rheumatology — Specialty Profile

Exploratory, not prescriptive. This profile blends hard data (pay, match rates, burnout, demographics — each sourced and dated) with generalizations and synthesized online opinion about culture and "who fits." It's here to help you get curious and go find out for yourself — not to tell you who to become. Numbers marked ⟳ verify change every year; check the linked source before you quote one. Last reviewed: 2026-07-25.

Also called: rheum. Subspecialty fellowship of Internal Medicine, reached through an IM residency rather than straight from medical school. Scope: the immune system's attack on joints, connective tissue, and organs, covering rheumatoid arthritis, lupus, gout, vasculitis, and the rest of the autoimmune and inflammatory diseases. Organ systems: musculoskeletal + multisystem autoimmune.

The 30-second version

Rheumatology is internal medicine's diagnostic-detective corner, the specialty for complex, multisystem autoimmune puzzles that no single test can crack. A patient arrives with joint pain, fatigue, a rash, and abnormal labs that don't obviously fit together; the rheumatologist synthesizes the story, the exam, and the immunology into a diagnosis and then manages a chronic disease such as rheumatoid arthritis, lupus, vasculitis, or gout, often for a decade or more with modern biologic drugs. It is overwhelmingly outpatient, cerebral, and elective, with minimal-to-no overnight or weekend call, one of the most schedule-controllable careers in all of medicine. The trade: it is a cognitive (non-procedural) field whose base salary sits in the lower-middle of the IM subspecialty ladder, modest on paper, though in-office infusion revenue quietly changes that math. Reached through the IMG/DO-accessible IM route, it is one of the more genuinely first-gen-attainable good-lifestyle paths in medicine.

Quick dashboard (details and sources below)
Training after med school IM residency (3) + Rheumatology fellowship (2) = 5 yrs after med school
Total from college start ~13 years (4 undergrad + 4 med school + 3 IM residency + 2 fellowship)
Competitiveness (as an IM fellowship) Moderate. 99.0% fill in the Fall 2025 Match (appointment year 2026), 385 applicants for 302 positions, and reachable for a solid applicant ⟳
Typical full-time pay ~$285,000 (Medscape) to ~$325,000 (Doximity); ~$300,000 consensus ⟳
Pay range (structure) low/academic/new ~$220k · median ~$260k (FastRVU's modeled ladder) · infusion-owning partners $320k–$600k+ ⟳
Lifestyle Outpatient, predictable, minimal call — among the most controllable in medicine
Burnout Middle-to-lower tier (data noisy on tiny samples) ⟳
% women ~50% of the practicing workforce; ~66% of fellows ⟳
DO / IMG accessibility Notably open — 16.4% DO and 48.8% IMG of the 299 fellowship positions filled for AY 2026 ⟳

What they actually do

Rheumatologists diagnose and manage autoimmune and inflammatory diseases of the joints, connective tissue, and, because these diseases are systemic, often the skin, kidneys, lungs, blood vessels, and nervous system too. The core skill is clinical reasoning: most rheumatic diseases have no single confirmatory test, so the diagnosis is a synthesis of a long history, a careful whole-body physical exam, imaging, and a panel of imperfect labs. The bread and butter is common inflammatory disease (rheumatoid arthritis, gout, lupus, osteoarthritis, spondyloarthritis) punctuated by genuine "zebras" like the vasculitides. Once diagnosed, these are chronic conditions, so the work is heavily longitudinal: rheumatologists follow the same patients for years, adjusting immunosuppressants and biologic drugs that have transformed what were once crippling diseases into manageable ones.

The work is cognitively dense rather than physically brutal. Days are full of long, complex histories, medication management, and the field's signature administrative grind, relentless prior authorizations for expensive biologics. It is a mostly outpatient specialty; inpatient work is consult-based and daytime, and there are few procedures that pull a rheumatologist back to the hospital overnight.

Representative procedures: arthrocentesis (joint aspiration) · intra-articular and soft-tissue corticosteroid injections · musculoskeletal (MSK) ultrasound, increasingly ultrasound-guided injection · nailfold capillaroscopy · management (not typically performance) of in-office biologic infusions.1 Compared with a procedural IM subspecialty like GI or cardiology, the procedure list is short, because this is fundamentally a cognitive specialty.

A day in the life: A typical clinic day runs roughly 8 hours seeing about 20–25 patients, on a predictable, pre-booked schedule with minimal-to-no overnight or weekend call in most settings.2 You move between new-patient consultations (an hour of history-taking and exam to untangle an undifferentiated case) and follow-ups (managing established RA, lupus, or gout). Genuine emergencies exist (giant cell arteritis threatening vision, a severe lupus flare, acute vasculitis) but middle-of-the-night hospital runs are rare. The fatigue at day's end is administrative and mental (documentation, prior-auth battles) rather than the sleep-deprivation of shift work.

The training path & time to completion

This is a subspecialty reached through internal medicine, in a two-step entry. You do not match into rheumatology from medical school; you first complete an IM residency, then apply to a rheumatology fellowship.3

MD or DO (4 yrs) → Internal Medicine residency (3 yrs) → Rheumatology fellowship (2 yrs) → board-eligible with ABIM Rheumatology.3

  • IM residency (3 yrs): ACGME-accredited categorical internal medicine, the shared trunk for all IM subspecialties.3
  • Rheumatology fellowship (2 yrs): the ACGME-accredited adult rheumatology standard. Some fellows extend a 3rd year for research or physician-scientist (e.g., T32) tracks, but 2 years is the required minimum for board eligibility.3
  • Board: the American Board of Internal Medicine (ABIM), in Rheumatology. You must first be certified (or board-eligible) in Internal Medicine, complete the 2-year fellowship, and pass the ABIM Rheumatology Certification Examination.3
  • Total after medical school: 5 years (3 IM + 2 rheum). Total from the start of college: ~13 years (4 undergrad + 4 med school + 3 + 2).
  • Pediatric rheumatology is a separate track. A 3-year fellowship after a pediatrics residency, boarded by the American Board of Pediatrics rather than the adult pathway described here.3

How competitive is it? (as an IM fellowship)

Rheumatology is matched through the NRMP Medicine and Pediatric Specialties Match, the "Fall Match" or Specialties Matching Service, a separate process from the main residency Match, entered during IM residency.3 The honest read: moderately competitive, and it fills almost completely, and a solid rather than superstar applicant can realistically target it.

  • Fill rate 99.0%. In the Fall 2025 Match (appointment year 2026), 133 rheumatology programs offered 302 positions and 299 filled, leaving three programs with a vacancy. NRMP grouped it with the IM subspecialties "offering at least 150 certified positions and filling over 98 percent of positions."34
  • Where it sits among IM subspecialties (AY 2026 fill rates): Cardiology 100% (1,347 positions) · GI 99.5% (759) · Heme/Onc 99.5% (809) · Rheumatology 99.0% (302) · Pulm/Critical Care 98.8% (844), well above the workforce-shortage fields like adult infectious disease (~60.9%) and geriatrics (~38.9%).3 Rheum is a mid-sized subspecialty (far fewer slots than cardiology or GI) that nonetheless fills at the top of the pack.
  • Growing and slowly toughening. Positions rose from 276 (AY 2024) to 287 (AY 2025) to 302 (AY 2026);4 a 12-year analysis found fellowship positions expanded 33.7% while the field became "increasingly competitive with rising USMLE scores and research experience requirements."35
  • Applicant-to-position ratio: about 1.27 applicants per position. 385 applicants ranked rheumatology programs for the 2026 appointment year against 302 positions, and 299 matched, so 86 of the people who ranked the field did not land in it. Some of them matched a subspecialty they preferred, and NRMP does not break that out. The report never prints the ratio, and it publishes both numbers it takes in the same table row.4 ⟳

The key context: because entry runs through internal medicine, one of the most IMG- and DO-accessible residencies, and because the fellowship itself fills strongly without being hypercompetitive, rheumatology is one of the more realistically attainable good-lifestyle subspecialties (see the FLI angle).

Compensation — the robust version

Rheumatology is a cognitive (non-procedural) specialty near the bottom of the IM subspecialty pay ladder. On Medscape 2026 it is tied with endocrinology at $284,000, a shade above infectious disease at $282,000, and well below nephrology ($359,000), GI ($530,000) and cardiology ($575,000). The single most important thing to understand about the money: the biggest lever separating a well-paid rheumatologist from an average one is in-office infusion and biologics revenue (buy-and-bill) rather than office-visit volume. A note on sources first: self-reported physician surveys (Doximity) run ~$40–50K higher than Medscape, and both sit above the wRVU productivity ladder used below, which comes from FastRVU, an aggregator publishing its own modeled benchmarks rather than a licensed survey table. Treat FastRVU as a guide to structure and Doximity/Medscape as the anchors for headline magnitude.6

National number. Depending on source and definition, rheum lands from ~$284,000 (Medscape 2026, 2025 data) to ~$324,954 (Doximity 2025, 2024 data), with FastRVU's modeled median employed comp near $260,000. A defensible "typical" figure for mid-2026 is ~$300,000 total compensation.6 ⟳

Bottom-tier on the headline surveys. Medscape ranked rheumatology in the bottom 4 of 29 specialties, statistically tied with endocrinology ($284k) and infectious disease ($282k), and far below the procedural IM fields at nephrology $359k, general IM $307k, GI $530k, and cardiology $575k.6 The ~$41K Doximity-against-Medscape gap is likely sample and selection bias (academic against private mix).6 ⟳

The spread (structure). Self-reported full-time range runs $191,000–$600,000.6 On FastRVU's modeled productivity ladder: low producers (<4,100 wRVU) ~$220,000 · median (4,900 wRVU) ~$260,000 · high producers (>5,700 wRVU) ~$320,000, at ~$53 per wRVU (range $50–$58 by setting).6 ⟳

Starting against experienced: the practice model matters more than tenure. New/early-career attendings cluster in the ~$220k–$260k low-producer and median band, solo or newer private-practice owners run below average until they build a patient panel and an infusion base. Experienced, high-producing, or practice-owning rheumatologists reach the top of the range, $320k–$600k+, driven by wRVU productivity and infusion-center ownership.6 ⟳ (Context: average student debt at graduation ~$205,000.)6

The income lever is in-office infusion and biologics (buy-and-bill). This is the defining feature of rheumatology economics. Buy-and-bill = the practice purchases the biologic drug, administers it in-office, and bills the payer at average selling price + 6%, keeping the spread. The math, as FastRVU's infusion-center model works it, is substantial:

  • Drug-margin: e.g., a Remicade infusion acquired ~$5,200 and reimbursed ~$5,512 nets ~$312/infusion, ~$2,496/patient/year. A panel of 150 infusion patients (~1,200 infusions/yr) at ~$300 spread ≈ ~$360,000/yr in drug-margin income; biosimilar margins run even higher.7 ⟳
  • Administration RVUs on top: infusion CPT codes generate ~1.5–2.26 wRVU each; a 1,500-infusion practice ≈ ~$179,000 in administration income.7 ⟳
  • Total infusion revenue scenarios (practice gross, not take-home): conservative (800 infusions) ~$322K · moderate (1,500) ~$603K · aggressive (2,500) ~$1.0M, and this flows materially into owner and partner comp.7 ⟳
  • Net effect: adding an infusion model can lift total comp to ~$320,000–$385,000 against the ~$260K median.6 This is why "low-paid" rheumatology often isn't: the modest base is respectable, and infusion revenue is what closes the gap to the procedural subspecialties. ⟳

Other levers. Joint injections and MSK ultrasound add procedural wRVUs on a low-RVU cognitive base; high-volume injection/infusion practices exceed median productivity.6 Locum tenens is a strong supplemental lever precisely because the work is portable and in short supply: W-2 employed ≈ ~$156/hr vs. locum $160–$200/hr; hybrid arrangements can reach ~$360K.62 ⟳

Geography. ZipRecruiter (aggregator, directional) puts the highest-paying state at Washington ~$355,063/yr and the lowest at Florida ~$234,272/yr, with Alaska, Oregon, Massachusetts, North Dakota, and Wisconsin also named among the top and Louisiana, Florida, and Hawaii among the lowest.6 As with most specialties, lower-cost, rural, and underserved markets often pay higher nominal comp than prestige coastal metros because of recruitment premiums, and the severe shortage (below) makes those premiums meaningful. A clean rheum-specific urban and rural table doesn't exist in the surveyed sources. ⟳ verify exact metro/rural rheum numbers.6

Academic vs. private. Academic hospitals ~$230,000 (AAMC academics-only ~$239,000) against non-academic hospitals ~$294,000, roughly a 22% academic discount, which is the same gap as non-academic paying about 28% more. Corporate and group private practices run above average; government (VA or city) below; solo private practice is highly variable, with new owners below average and established owners with infusion among the highest.6 ⟳

The trend that colors all of it. Comp growth is weak and lagging peers. Doximity showed rheum +6.4% in 2024, but Medscape showed 0% change 2024→2025, and rheumatologists themselves expect 0% growth next year (against 9–10% expected in cardiology and radiology).6 Only ~60% feel fairly compensated.6 The two structural forces are the biologics boom (an expanding drug armamentarium that drives infusion volume and buy-and-bill margin, the main path above median) and a severe workforce shortage (below), which puts real upward pressure on recruitment bonuses and rural premiums even as the RVU base stays low.768 ⟳

Lifestyle & the controllable-calendar bargain

The single most-cited pro of rheumatology: you control your calendar and your nights. It is overwhelmingly outpatient, clinic-based, and elective, with predictable, pre-booked schedules and minimal-to-no overnight or weekend call in most practice settings.2 Emergent and overnight demands are among the lowest of any IM subspecialty, with no procedures that pull you back at 2 a.m. and no ICU ownership. It is repeatedly cited as one of the easiest specialties to work part-time, job-share, or scale back in, which makes it attractive to parents and to anyone wanting a sustainable, long-horizon career. The locum market is strong precisely because the work is portable and in short supply.2

The con is the same coin flipped: the work is cognitively dense rather than physically brutal, with long, complex histories, heavy medication management, and a relentless prior-authorization and insurance-battle load over expensive biologics. The fatigue is administrative and mental rather than sleep deprivation. There is also little acute-care adrenaline and few procedures, which is a genuine drawback for hands-on personalities.

Lifestyle rating: 5/5. Near the top of the entire field for schedule control and predictability, alongside dermatology, allergy, and endocrinology.2

Wellbeing — the honest read

Burnout sits middle-to-lower tier, but the data is noisy. Medscape's rheumatology burnout numbers have bounced dramatically year to year (54% in 2017, 38% in 2018, 41% in 2019, 46% in 2020, ~50% at the 2021 pandemic peak), which experts attribute largely to tiny sample sizes (~120 rheumatologists per survey, ~1% of respondents) rather than real swings, and one ACR commentator noted the fluctuations lack any "intellectual reason." Outside pandemic spikes, rheum consistently sits in the middle-to-lower burnout tier, and the top driver, as everywhere, is bureaucratic and paperwork load, which for rheum specifically means the biologic prior-authorization grind.2 ⟳

Satisfaction & happiness. Rheumatology generally reports high career satisfaction and strong would-choose-the-specialty-again numbers; practitioners cite intellectual reward and long-term patient relationships. One nuance to be honest about: in Medscape's 2025 Mental Health & Well-Being report, 67% of rheumatologists said doctors in their field can be happy and well-balanced, a solid majority but only lower-middle in that particular ranking.2 On a separate Medscape "happiness outside of work" measure, rheumatology sat near the lower end (~51%).9 The honest synthesis: the lifestyle is excellent, but paperwork friction keeps it off the top of "happiest" lists. ⟳

Career longevity is a real strength. This is one of rheumatology's quiet advantages. Low physical demand, no night call, and the ability to taper hours make it a specialty people practice comfortably into their 60s and 70s. The wear is cognitive rather than physical, so unlike shift-heavy or procedure-heavy fields, "can you still do this at 65?" is an easy yes.2

Who's in the field (demographics)

  • Women: rheumatology is majority-women in the pipeline and heading there in practice. ~66% of adult rheumatology fellows are women (a corroborating peer-reviewed figure put fellows at 60.8% female in 2018, vs. 42.8% of categorical IM residents); the practicing workforce is ~50% women and trending toward a female majority as the pipeline matures.5 ⟳
  • DO: 16.4% of the 299 positions filled for AY 2026 (49 fellows), and the trend the ACR analysis found has continued: ~6.6% in 2008, ~14.5% in 2020, 16.2% of positions offered in 2026.54 ⟳
  • IMG: 48.8% of the 299 positions filled for AY 2026 (40 US IMGs plus 106 non-US IMGs), one of the higher IMG shares among IM subspecialties and a real entry point. On the positions-offered denominator the share has risen every cycle since 2023: 39.2% (2023) · 42.8% (2024) · 47.0% (2025) · 48.3% (2026).54 ⟳
  • URiM: a diversity study found no significant trends or differences in the proportion of Black or Hispanic applicants vs. fellows in rheumatology (2008–2018), meaning URiM representation was flat and low, consistent with IM subspecialties broadly. Precise rheum-specific Black% and Hispanic% figures were not separately reported in accessible sources; ⟳ verify against AAMC Report on Residents Table B7.5

Culture, personality & the online stereotypes

Who gravitates here: diagnostic detectives who love complex, multisystem autoimmune puzzles where no single test gives the answer, the "clinical reasoning as a craft" crowd; pattern-recognizers and physical-exam lovers (joints, skin, nailfolds, the whole-body exam still matters); longitudinal-relationship people who want to follow chronic patients for a decade-plus; cerebral, immunology-curious types who enjoy the "nerdy hardcore science" plus modern imaging (MSK ultrasound, MRI); and lifestyle-conscious physicians who want intellectual depth without sacrificing evenings, weekends, and family. As always, plenty of people in the field do not fit any single mold.2

The stereotypes. Community caricatures rather than facts, each with an unfair edge:

  • "The great diagnosticians / House MD." Flattering and partly earned, since rheum genuinely is a diagnostic-reasoning specialty. Unfair edge: it romanticizes rare "zebras" when most days are managing well-understood RA, gout, lupus, and osteoarthritis.
  • "Zebra-hunters." The idea that rheumatologists chase exotic diagnoses. Unfair: the bread and butter is common inflammatory disease, and good rheum is as much about not over-diagnosing.
  • "Lifestyle + cerebral but modest pay." Largely accurate as a stereotype, but the "modest pay" half misleads because it ignores infusion and buy-and-bill income that can substantially close the gap.
  • "Everyone's fibromyalgia dumping ground." The frustrating one: because rheum sees chronic pain, other specialties reflexively refer every unexplained pain and fatigue their way. Rheumatologists push back that this is a workload and morale problem rather than the specialty's identity, and that fibromyalgia is often better managed elsewhere.

What people say online (synthesized and paraphrased, not quotes): Across trainee and physician forums, residents describe rheum as the "smart person's lifestyle specialty," intellectually satisfying with humane hours and no call, a common landing spot for people who love IM's thinking but want out of the hospital and off nights. The recurring gripe is consistent: prior authorizations and insurance battles over biologics are the true daily enemy rather than patient acuity. The fibromyalgia-referral fatigue shows up as a frequent, half-joking lament. Pay is discussed with nuance: base salary looks unimpressive next to GI and cards, but posters repeatedly note that owning an infusion suite changes the math a lot and that demand is so high jobs are plentiful and geographically flexible. There's strong consensus that it's IMG/DO-friendly and one of the more attainable fellowships for a great lifestyle without a hypercompetitive match.2

Voices from the field. Paraphrased from public writing, with links to the originals:

  • A rheumatology fellowship director describes rheumatologists as detail-oriented "storytellers" who love hearing how an illness unfolded over time, emphasizes that most rheumatic diseases lack a single definitive test, making diagnosis an endlessly gratifying craft, and cautions applicants to shadow rather than judge the field by one hard case.10
  • A rheumatologist frames the appeal as a blend of clinical medicine, high-tech imaging, and hardcore immunology, paired with down-to-earth colleagues whose measured commitment leaves real room for family, plus deeply gratifying long-term relationships now that biologics make most RA patients do well.11
  • A rheumatologist writing in ACR's magazine contextualizes the volatile burnout numbers as statistical noise from small samples rather than a real crisis, pointing to bureaucratic burden as the genuine stressor.2

Why people choose it / why people leave

Why choose it: elite schedule control (outpatient, predictable, minimal-to-no call, part-time-friendly) · intellectually rich diagnostic reasoning and immunology rather than algorithmic medicine · deep, long-term patient relationships in a field transformed by biologics (you genuinely make people better now) · booming demand and job security nationwide, so you can practice almost anywhere · a reasonably accessible fellowship, a realistic route to a great-lifestyle cerebral career without a brutal match · excellent career longevity.

Why leave or avoid it: base salary is modest relative to procedural IM subspecialties, since the money mostly comes from infusions and volume rather than the office visit · prior-authorization and insurance warfare over biologics is a constant, morale-sapping grind · the "fibromyalgia and chronic-pain dumping ground" referral load · cognitively dense clinic days with heavy documentation · few procedures and no acute-care adrenaline.

Best fit if: you love solving multisystem puzzles · you value clinical reasoning and the physical exam · you want long-term relationships with chronic patients · you prioritize controllable hours and career longevity over top-tier pay.

Not for you if: you need procedural/hands-on work or acute-care adrenaline · you want the highest possible income · you dislike chronic-pain and hard-to-cure patient populations · you have low tolerance for insurance/prior-auth paperwork.

The FLI angle — Rheumatology for first-gen, low-income & immigrant students

Rheumatology is one of the best-kept FLI secrets in medicine, a cerebral, great-lifestyle career reachable through the accessible internal-medicine route.

Where rheum fits FLI realities well:

  • An accessible two-step pathway. The road runs through internal medicine, itself one of the more IMG- and DO-accessible residencies, and then a rheumatology fellowship that fills strongly but is not hypercompetitive. IMGs and DOs have steadily grown their share of matched fellows: US-DOs rose from ~6.6% in 2008 to ~14.5% in 2020 and 16.4% for AY 2026, and the total IMG share reached 48.8% of filled positions for AY 2026, up from 39.2% three cycles earlier. A FLI student who lands IM can realistically reach rheumatology.54
  • Elite lifestyle without the pedigree tax. You get controllable hours, no call, and long career longevity, benefits usually associated with the hypercompetitive lifestyle fields, through a more attainable door.2
  • A severe shortage means leverage. The documented, worsening workforce gap means strong job security, negotiating power, geographic freedom, and loan-repayment and underserved-area incentives, all disproportionately valuable to someone without a financial safety net.8
  • Infusion income closes the pay gap. The "modest pay" reputation understates real earnings. A respectable base (~$285k–$325k) plus infusion and buy-and-bill revenue, which FastRVU's model puts in the hundreds of thousands, means a FLI physician can build genuine wealth here rather than just a comfortable schedule.67

Risks to name honestly:

  • The base salary really is lower-tier. Without building infusion or productivity, rheum sits at the bottom of the IM-subspecialty pay ladder, and if maximizing income fast is the goal, procedural fields pay more, sooner. The infusion upside typically requires ownership or partnership, which takes years to build.6
  • The paperwork grind is real. The prior-authorization burden over biologics is the field's most-cited daily frustration, and it falls on you regardless of practice model.2
  • It's two extra training years beyond a 3-year IM residency, so five years post-med-school before attending pay, against finishing as a general internist sooner. Weigh that if you need to start earning quickly.3

Bottom line: rheumatology is a modest-but-respectable-pay, elite-lifestyle, high-demand, genuinely intellectual career reachable through the IMG- and DO-friendly IM route, one of the most FLI-attractive good-lifestyle paths in all of medicine. You don't have to trade your health or your family life for a stable, well-paid, intellectually satisfying career. Shadow a rheumatology clinic, and ask about the prior-auth reality, before you commit.10

Sub-subspecialties & niches

Rheumatology has fewer formal sub-boards than some fields, but several distinct career flavors exist:26

  • Pediatric rheumatology (reached via pediatrics or med-peds, not the adult IM route), a separate 3-year fellowship boarded by the American Board of Pediatrics. Mission-driven and in profound shortage: the 2026 fellowship match filled only ~24 of 44 positions (~54%), leaving large swaths of the country with no pediatric rheumatologist at all. Lower pay, highest need.23
  • Interventional / MSK ultrasound rheumatology. A growing niche building procedural, ultrasound-guided injection and diagnostic-imaging practices; adds a hands-on, revenue-generating dimension to an otherwise cognitive field.26
  • Lupus & vasculitis centers of excellence. Academic/tertiary subniches for those drawn to the most complex multisystem autoimmune disease, clinical trials, and cutting-edge biologics.2
  • Infusion-center ownership. Less a clinical subspecialty than a practice model, but the defining economic path in the field (see Compensation).7

Fun facts

  • Rheumatologists follow many patients for a decade or more, among the longest continuous doctor-patient relationships in medicine.2
  • Most rheumatic diseases have no single confirmatory test. Diagnosis is a pattern-and-story synthesis, which is exactly why the "medical detective" reputation sticks.2
  • MSK ultrasound has become a signature in-office skill and subculture; some rheumatologists build entire interventional/ultrasound-guided injection practices.2
  • FastRVU's modeled scenarios put an infusion center ("buy-and-bill" of biologics) at anywhere from ~$320K to over $1M in annual practice income depending on volume, the reason "low-paid" rheumatology often isn't.7
  • The specialty faces a severe, well-documented workforce shortage, with the ACR projecting demand far outstripping supply, especially in rural and underserved areas, making it one of the most secure job markets in medicine, roughly half of current rheumatologists are Baby Boomers likely to retire within ~15 years.8

Sources

Footnotes

  1. Procedures (arthrocentesis, intra-articular/soft-tissue injections, MSK ultrasound) add procedural wRVUs on a low-RVU cognitive base; high-volume injection/infusion practices exceed median productivity. Exact per-procedure reimbursement (CPT 20610/20611/76881) not enumerated in surveyed sources — verify. FastRVU (https://fastrvu.com/specialties/rheumatology). ↩

  2. Lifestyle, wellbeing, culture, online sentiment, and sub-subspecialty notes. ~8-hr clinic days seeing ~20–25 patients, minimal-to-no call, part-time-friendly, portable locum market, cognitively-dense-not-physically-brutal fatigue; burnout volatility on tiny samples (54%/38%/41%/46%/~50% across 2017–2021) with bureaucratic/prior-auth load as top driver; 67% "can be happy/well-balanced" (Medscape 2025, lower-middle); excellent career longevity into 60s–70s; culture/who-gravitates; paraphrased Reddit/SDN sentiment; pediatric-rheum 2026 match ~24/44 (~54%); MSK-ultrasound and lupus/vasculitis niches. Barton Associates, Rheumatology Salary Guide 2026 (https://www.bartonassociates.com/physician-rheumatology-salary-guide/); The Rheumatologist, "Medscape Survey Suggests 50% of Rheumatologists Experience Burnout" (2021, https://www.the-rheumatologist.org/article/medscape-survey-suggests-50-of-rheumatologists-experience-burnout/); Healthgrades summary of Medscape 2025 Mental Health & Well-Being Report (https://resources.healthgrades.com/pro/happiest-physicians-by-specialty); ACR, "2025 Rheumatology Fellowship Match Day" (pediatric fill rate) (https://rheumatology.org/press-releases/2025-rheumatology-fellowship-match-day-fill-rates-remain-strong-but-workforce-gaps-persist); FastRVU infusion article (above); paraphrased r/rheumatology, r/IMslave, r/Residency, SDN (synthesized, not quoted). ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19 ↩20

  3. Training pathway, board certification, two-step entry, and competitiveness/fill data. Rheumatology is a 2-year ACGME adult fellowship after a 3-year IM residency, boarded by ABIM Rheumatology (IM certification must precede subspecialty certification). ABIM Rheumatology certification policy (https://www.abim.org/certification/policies/internal-medicine-subspecialty-policies/rheumatology/, 2026); NRMP, "NRMP Celebrates Results for the 2025 Medicine and Pediatric Specialties Match" (Dec 2025, appointment year 2026: 302 certified positions, 99.0% fill; comparative IM-subspecialty fill rates) (https://www.nrmp.org/about/news/2025/12/nrmp-celebrates-results-for-the-2025-medicine-and-pediatric-specialties-match/); applicant and position detail at 4; The Rheumatologist, "2024 Rheumatology Fellowship Match Day Results" (AY 2024: 284/287 positions = 99%, ~132 programs) (https://www.the-rheumatologist.org/article/2024-rheumatology-fellowship-match-day-results/, 2024); Medscape, "Rheumatology Fills Over 97% of Fellowship Programs for 2024" (https://www.medscape.com/viewarticle/998907). Pediatric rheumatology is a separate 3-year pediatrics-based fellowship. ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12

  4. Fellowship match detail, including the applicant-to-position ratio. NRMP, Results and Data: Specialties Matching Service, 2026 Appointment Year (February 2026). Table 1A, rheumatology: 133 programs, 302 positions offered, 385 applicants, 299 matches, 99.0% filled, 3 programs left with a vacancy; 114 of the applicants and 104 of the matches were graduates of US MD schools. 385 ÷ 302 = 1.27 applicants per position. Table 6A gives the position trend: 302 in 2026, 287 in 2025, 276 in 2024, 271 in 2023, 272 in 2022. Table 1A also carries the comparison IM subspecialties quoted above (cardiology 1,347 positions at 100.0%, gastroenterology 759 at 99.5%, hematology and oncology 809 at 99.5%, pulmonary and critical care 844 at 98.8%, infectious disease 447 at 60.9%, geriatric medicine 388 at 38.9%) and pediatric rheumatology (33 programs, 44 positions, 25 applicants, 24 matches, 54.5% filled). https://www.nrmp.org/wp-content/uploads/2026/02/SMS_Results_and_Data_Report2026.pdf. Correction 2026-08-13: this profile previously stated that the applicant-to-position ratio was "not published as a discrete rheumatology figure," and asked a reader to verify it against the 2025 edition of this same report. Both figures the ratio requires are printed side by side in Table 1A, and have been each year. The same edit corrected the position trend, which had labeled the 287 figure as AY 2024; 287 is AY 2025 and AY 2024 was 276. Applicant type, Table 2, AY 2026: of the 299 filled positions, US MD 104 (34.8%), US DO 49 (16.4%), US IMG 40 (13.4%), non-US IMG 106 (35.5%), Canadian 0, so total IMG is 146 of 299, 48.8%. The five-year trend tables give the shares on the positions-offered denominator: IMG 48.3% (2026) · 47.0% (2025) · 42.8% (2024) · 39.2% (2023) · 42.7% (2022), and DO 16.2% · 14.3% · 13.8% · 13.3% · 14.0%. Corrected 2026-08-17: the dashboard row read "~15% DO, ~39% IMG of filled fellowship positions" with no year, and the demographics bullets carried the same pair dated 2020 from a 12-year ACR analysis ending that year. The current IMG figure is nearly ten points higher, and it was in this report, which this footnote already quotes for six other rows. The direction strengthens the FLI argument rather than weakening it: rheumatology is more open than the dashboard said, and the IMG share has risen every cycle since 2023. The ACR series is kept as the trend it is. The dashboard also called it "the 2026 Fall Match," which the body and 3 correctly identify as the Fall 2025 Match for appointment year 2026. ⟳ ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7

  5. Demographics and the 12-year competitiveness/origin trend. Fellows ~66% women (MDedge/The Hospitalist, "Women in rheumatology," https://community.the-hospitalist.org/content/women-rheumatology-look-back-look-forward); 60.8% female fellows in 2018 vs. 42.8% categorical IM residents, plus flat URiM trends (J Gen Intern Med, "Diversity Within the Most Competitive Internal Medicine Fellowships: Trends 2008–2018," https://link.springer.com/article/10.1007/s11606-020-06008-5); practicing workforce ~50% women (MDedge, above; 2015 ACR/ARHP Workforce Study, https://acrabstracts.org/abstract/2015-acrarhp-workforce-study-wfs-adult-rheumatology-specialists-in-the-united-states-effect-of-gender-and-generation/). US MD/DO/IMG shares of filled positions (2020: US MD 43.4%, US DO 14.5%, US IMG 14.5%, non-US IMG 24.8%, total IMG ~39%; positions +33.7% over the window): ACR Meeting Abstracts, "What's Trending? A 12-Year Analysis of IMGs Matching into Rheumatology Fellowship Programs" (data 2008–2020) (https://acrabstracts.org/abstract/whats-trending-a-12-year-analysis-of-international-medical-graduates-matching-into-rheumatology-fellowship-programs-in-the-united-states/). URiM race/ethnicity detail: verify against AAMC Report on Residents Table B7 (https://www.aamc.org/data-reports/students-residents/data/report-residents/2024/table-b7-residents-race-ethnicity-and-specialty). ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  6. National comp, IM-subspecialty ranking, spread, starting-vs-experienced, geography, academic-vs-private, employment models, and trend. Doximity 2025 Physician Compensation Report ($324,954 avg total comp, 2024 data; rheum +6.4%) (https://www.doximity.com/reports/physician-compensation-report/2025); Medscape 2026 ($284,000, 2025 data, "no change," bottom 4 of 29) via RheumNow (https://rheumnow.com/news/rheumatology-salaries-2025) and Becker's IM-subspecialty ranking (https://www.beckershospitalreview.com/compensation-issues/29-physician-specialties-ranked-by-annual-compensation-medscape/); MGMA/wRVU percentiles, productivity bands, comp-per-wRVU, and "infusion lifts comp to $320k–$385k" (FastRVU, https://fastrvu.com/specialties/rheumatology); self-reported $191k–$600k range, sign-on/relocation/CME bonuses, ~$205k debt, academic ~$230k vs. non-academic ~$294k (Physician Side Gigs, https://www.physiciansidegigs.com/average-rheumatologist-salary); AAMC academics ~$239k and Medscape/MGMA context (White Coat Investor, https://www.whitecoatinvestor.com/rheumatologist-salary/); state spread (Washington ~$355,063; Florida ~$234,272) (ZipRecruiter, aggregator/directional, https://www.ziprecruiter.com/Salaries/What-Is-the-Average-Rheumatologist-Salary-by-State) and top/bottom state list (Physicians Thrive, https://physiciansthrive.com/physician-compensation/rheumatologist-salary/); hourly/locum ($156/hr employed vs. $160–200/hr locum; hybrid ~$360k) (Barton Associates, https://www.bartonassociates.com/physician-rheumatology-salary-guide/); BLS general-IM proxy mean $267,200 (May 2025; no rheum-specific code), US Bureau of Labor Statistics, Occupational Employment and Wages — May 2025, Table 1 (https://www.bls.gov/news.release/archives/ocwage_05152026.htm). Updated 2026-08-18: this figure came from the Occupational Outlook Handbook pay table, which as of 2026-08-18 still prints May 2024 wages. It now comes from the Bureau's May 2025 release, published 2026-05-15. Urban/rural rheum-specific differential not cleanly published — verify. Corrected 2026-08-17: the academic-vs-private sentence called the gap between $230,000 and $294,000 "roughly a 28% academic discount". 28% is the premium computed off the academic base ($64,000 / $230,000 = 27.8%); a discount is computed off the non-academic base and is 21.8%. The percentage was reversing the direction of its own comparison. Both dollar figures are Physician Side Gigs' and are unchanged. Corrected 2026-08-17: the wRVU ladder, the ~$260,000 employed median and the "infusion lifts comp to $320k–$385k" figure are all FastRVU's own modeled benchmarks. Three places in the body credited them to MGMA instead: the dashboard's pay-range row, the national-number sentence, and the spread paragraph, which opened "By MGMA productivity (2024)". FastRVU's page says it is not a licensed MGMA table, so that label was false in all three. FastRVU is now named where a reader meets each number, because an aggregator figure stays where it is the only figure there is and puts the host in the visible sentence rather than only in this footnote. The "(2024)" production year went with the label: it was an MGMA vintage, and FastRVU publishes none. ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19 ↩20 ↩21

  7. In-office infusion / biologics buy-and-bill economics — the field's primary income lever. Buy-and-bill at ASP+6%; Remicade $312/infusion ($2,496/patient/yr); 150-patient panel ≈ ~$360k drug-margin; administration RVUs ≈ ~$179k on a 1,500-infusion practice; total infusion-revenue scenarios $322K/$603K/$1.0M (conservative/moderate/aggressive, practice gross). FastRVU, "Rheumatology Infusion Center Income 2026" (https://fastrvu.com/articles/rheumatology-infusion-center-income); mechanics/context: Altus Biologics (https://altusbiologics.com/how-can-buy-and-bill-help-my-rheumatology-practice/) and The Rheumatologist, "Managing an In-Office Infusion Practice" (https://www.the-rheumatologist.org/article/managing-an-in-office-infusion-practice/). Corrected 2026-08-17: FastRVU is now named in the body at the head of this section's arithmetic, and again in the Fun facts line and the FLI bullet that lean on it. No figure changed. Buy-and-bill is the page's central economic argument and every number in it rests on this one host, so a reader is told which host before reading them. ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7

  8. Workforce shortage — the key long-run pressure. ACR Workforce Study projected a shortfall of ~2,500 (later revised to ~3,800) rheumatologists, with a widening supply-demand gap modeled to 2030; roughly half of current rheumatologists are Baby Boomers likely to retire within ~15 years. ACR Convergence Today (https://www.acrconvergencetoday.org/future-rheumatology-supply-inadequate-for-demand/); ACR workforce initiative via Healio, "Stay popular, stay full" (https://www.healio.com/news/rheumatology/20241119/stay-popular-stay-full-acr-tackles-workforce-shortage-through-reimbursement-education). ↩ ↩2 ↩3

  9. Cross-specialty happiness reference — rheumatology near the lower end of Medscape 2024 "happiness outside of work" (~51%). Medscape 2024 Lifestyle Report via HCN/Healthgrades, as (https://resources.healthgrades.com/pro/happiest-physicians-by-specialty). ⟳ verify. ↩

  10. Philip Seo, MD (Johns Hopkins) — AMA, "What it's like to specialize in rheumatology: Shadowing Dr. Seo" (https://www.ama-assn.org/medical-students/preparing-residency/what-its-specialize-rheumatology-shadowing-dr-seo). ↩ ↩2

  11. Ronan Kavanagh, MD — "Why rheumatology is sexy," KevinMD (2011) (https://kevinmd.com/2011/12/rheumatology-sexy.html). ↩

Researched with AI assistance and reviewed by hand. How this site is made